Dimitris Anagnostakis

Mr. Dimitris Anagnostakis was born in 1964. He studied Pharmaceutical Science at the University of Patras.

He joined Boehringer Ingelheim Ellas SA in 1991 as a sales representative with further specialization in hospital products. During 1996-2002, he took on various positions in the company’s department of Pharmaceutical Marketing for the sector of Cardiology medicine, responsible for the launching of various new products in the treatment field of thrombolysis and hypertension. In the following two years (2002-2004), he becomes Head of Hospital Business Unit. After the company’s restructuring, he becomes Head of Marketing & Oncology Business in 2004, a position held until 2013.

For the subsequent period, he is been relocated to the Company’s head office in Ingelheim, Germany, as Regional Business Manager for Italy, France and Spain. Since July 2014, he is the President and Managing Director of Boehringer Ingelheim Ellas SA for Greece and Cyprus.

On behalf of Boehringer Ingelheim Ellas, Dimitris Anagnostakis is a member of the board of directors of Hellenic - German Chamber of Commerce (AHK), and member of the Innovation Task Force Group of AHK. Dimitris is also member of the board of directors of the Hellenic Association of Pharmaceutical Companies (SfEE) and holds the position of Secretary General and Chairman of the documentation committee.

Boehringer Ingelheim Ellas is a member of the Boehringer Ingelheim GmbH group of companies and is present in Greece for more than half a century. Boehringer Ingelheim was recently been awarded as being among the top 100 most innovative companies worldwide. In Greece, Boehringer Ingelheim is been rated among the top 10 pharmaceutical companies, with a total of 290 million euros in sales, 190 million euros of which are earnings from exports to 70 countries, summing up to 1% of the country’s total export revenues, independent of business field. The company employs 450 people, and owns a manufacturing facility for innovative medicines in Koropi since 1975. This plant has become the production and export hub for the company’s strategic products since 2012. During the decade of recession, the company invested over 100 million euros in the expansion of business operations and the conduct of clinical trials.

The company’s investment operations is been awarded with the Prix Galien distinction in 2019, as well as with other prices from various respected authorities. Boehringer Ingelheim Ellas SA is a member of the Panhellenic Exporters Association while leads the healthcare group of the Hellenic - German Chamber of Commerce.